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INTRODUCTION: While mutations in PIK3CA are most frequently (45%) detected in luminal breast cancer, downstream
PI3K/AKT/mTOR pathway activation is predominantly observed in the basal subtype. The aim was to identify proteins
activated in PIK3CA mutated luminal breast cancer and the clinical relevance of such a protein in breast cancer patients.
MATERIALS AND METHODS: Expression levels of 171 signaling pathway (phospho-)proteins established by The Cancer
Genome Atlas (TCGA) using reverse phase protein arrays (RPPA) were in silico examined in 361 breast cancers for their
relation with PIK3CA status. MAPK1/3 phosphorylation was evaluated with immunohistochemistry on tissue microarrays
(TMA)containing721primarybreastcancercorebiopsies toexplore the relationshipwithmetastasis-freesurvival.RESULTS:
In silico analyses revealed increased phosphorylation ofMAPK1/3, p38 and YAP, and decreased expression of p70S6K and
4E–BP1 in PIK3CA mutated compared to wild-type luminal breast cancer. Augmented MAPK1/3 phosphorylation was
most significant, i.e. in luminal A for both PIK3CA exon 9 and 20 mutations and in luminal B for exon 9 mutations. In 290
adjuvant systemic therapy naïve lymph node negative (LNN) breast cancer patients with luminal cancer, high MAPK
phosphorylation in nuclei (HR = 0.49; 95% CI, 0.25–0.95; P = .036) and in tumor cells (HR = 0.37; 95% CI, 0.18–0.79;
P = .010)was relatedwith favorablemetastasis-freesurvival inmultivariateanalyses including traditional prognostic factors.
CONCLUSION: EnhancedMAPK1/3 phosphorylation in luminal breast cancer is related to PIK3CA exon-specific mutations
and correlated with favorable prognosis especially when located in the nuclei of tumor cells.
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The Cancer Genome Atlas (TCGA) data on breast cancer have shown
that the PIK3CA mutation frequency could rise to 45% in luminal A
tumors compared to only 9% in basal tumors [1]. Remarkably, the reverse
protein phase array (RPPA) data of this study demonstrated that
phosphorylation of AKT, S6 and 4 EB-P1, typical markers of PI3K
pathway activation (PI3K-AKT signaling pathway in KEGG: http://
www.genome.jp/kegg-bin/show_pathway?hsa04151) were highly
expressed in basal-like and HER2 molecular subtypes and correlated
strongly with INPP4B and PTEN loss, and with PIK3CA amplification.
Moreover, protein and mRNA signatures of PI3K pathway activation
were enriched in basal-like over luminal A breast cancers [1].
Mutations in PIK3CA occur predominantly in two hotspot regions, i.e.
in the helical and kinase domains encoded by exon 9 and 20, respectively.
COSMIC, the catalogue of somatic mutations in cancer (http://cancer.
sanger.ac.uk/cancergenome/projects/cosmic/) reported so far 2745 mis-sense mutations for PIK3CA in breast carcinomas, which were located in
exon 9 and more frequently in exon 20.
It has been reported that the PIK3CA mutation status between
primary and corresponding metastatic disease can be discordant [2].
Interestingly, single cell PIK3CA mutational analyses revealed heteroge-
neity in circulating tumor cells andmetastases compared to primary breast
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for the distinct molecular subtypes in relation toPIK3CAmutation status.
For example, prolonged survival was observed in ER-positive early disease
patients treated with adjuvant tamoxifen and in advanced disease patients
treated with first-line aromatase inhibitors for those with PIK3CAmutant
tumors [4,5]. In contrast, PIK3CA mutations in HER2+ patients were
linked to trastuzumab therapy resistance [6–8]. This resistance might be
due to co-occurrence of both oncogenes or to tumor cell heterogeneity
with underrepresented trastuzumab responsive HER2+ clones.
In order to understand the apparent disconnection in breast cancer
between genetic activation through PIK3CA oncogenic driver mutations
and its downstream PI3K/AKT/mTOR signaling cascade, we evaluated
in especially luminal tumors pathway proteins for their relation with
PIK3CA mutations. Therefore, TCGA in silico RPPA-database of 171Figure 1. Overview of the study design. Figure 1A. In-silico data used
expression and/or phosphorylation patterns related to thePIK3CAmutatio
to explore the subcellular localization of the discovered potential biom
mutation status and prognosis. Abbreviations: IHC: Immunohistochemiscancer-related (phospho) proteins from 361 breast cancer specimens were
stratified by type of PIK3CA mutation and molecular subtypes.
Expression or phosphorylation of seven proteins correlated significantly
withPIK3CA status in luminal breast cancer. PhosphorylatedMAPK1/3,
as most significant up-regulated protein, was further explored on TMAs
containing 721 primary breast cancer specimens, including a subset of
luminal tumors from 290 systemic untreated LNN patients, to address
the prognostic value of this phosphorylated kinase (Figure 1).Materials and Methods
Databases and Software Packages
We have used the quantified expression of 171 cancer-related
proteins and phosphoproteins by RPPA of 403 primary breast cancerfrom the TCGA consortium to identify potential biomarkers (protein
n status adjusted for subtype. Figure 1B. Tissuemicroarrays data used
arker phospho-MAPK1/3 and its correlation with subtypes, PIK3CA
try; TMA: Tissue microarrays; LNN: Lymph Node Negative.
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data used by us were deposited [1] and can be retrieved at TCGA
portal at https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm.
The tumors were selected based on their known PIK3CA mutation
status and molecular subtype [9]. Of the 403 tumors, 366 specimens
with a single PIK3CA mutation within the hotspot in exons 9 or 20
or wild-type were selected for further analyses, excluding tumors with
PIK3CA double mutations. Five additional specimens were excluded,
because 4 samples belonged only to the normal-like subtype and oneFigure 2. Data analysis flowchart to discover potential protein biomark
identify the association of the PIK3CA mutation with the protein expr
Array (RPPA) in silico data from the TCGA consortium on 361 breastspecimen lacked subtype classification. In the remaining 361 tumors,
either mutant (N = 94) or wild-type (N = 267) for PIK3CA, the
protein expression and phosphorylation levels were analyzed
irrespective of molecular subtype as well as stratified by subtype
(using the PAM50 classification) (Figure 2).
Data Analyses and Statistics
Differences between groups were examinedwith a two-tailed student's
t-test or when not normally distributed with the Mann–Whitneyers for breast cancer. The figure shows the detailed criteria used to
ession and phosphorylation patterns using Reverse Phase Protein
tumors and 171 proteins or phosphoproteins.
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protein expression and phosphorylation levels to establish their
relationships with the PIK3CA genotype and molecular subtypes.
The residuals of the regression analyses were afterwards checked
for their constant variance by the Breusch-Pagan/Cook-Weisberg
test for heteroscedasticity and for their normality. In multiple
linear regression analyses, the PIK3CA wild-type basal subtype was
used as reference to which the other subtypes and their PIK3CA
status were compared. Proteins significant after these regression
analyses were subsequently investigated for their relationship with
PIK3CA genotype in luminal A and B specimens and also for their
associations with exon 9 and exon 20 mutations, separately. The
protein expression and phosphorylation levels were visualized with
boxplots to illustrate the levels in luminal A and B PIK3CA
wild-type or mutant with the levels obtained in basal wild-types
(Figure 3).
The Cox proportional hazard model was used in univariate analysis
to compute the hazard ratio (HR) for metastasis-free survival (MFS).
The HR was presented with its 95% confidence intervals (95% CI).
Survival curves were generated using the Kaplan–Meier method and a
log rank test was applied to test for differences. MFS was defined as
the time elapsed between the date of diagnosis and the date of distant
metastatic relapse. In multivariate analysis, the biomarker was added
to the base model of traditional prognostic factors for early breast
cancer disease, i.e., age at diagnosis, menopausal status, tumor size,
and tumor grade. Analyses were executed in STATA statistical
package, release 14 (STATA Corp., College Station, TX). All P-values
were two-sided, P b .05 was considered statistically significant.
Immunohistochemistry and Evaluation of MAPK1/3
Phosphorylation
Tissue microarrays (TMAs) of formalin-fixed, paraffin-embedded
primary breast cancer specimens were described previously [11], andwere
immunocytochemically stained according to the procedures previouslyTable 1. Protein Alterations in Breast Cancer Related with PIK3CA Genotype Irrespective of Molecu
P-Values in Statistical Analysis for Protein Alterations in Relation to PIK3CA Mutation Status Alone
Student t-test or Mann–Whitney
Protein Alteration PIK3CA
MAPK1/3 Phosphorylation of T202/Y204 b0.001
4E.BP1 Expression b0.001
p70S6K Expression 0.010
p38 Phosphorylation of T180/Y182 b0.001
YAP Phosphorylation of S127 0.003
4E.BP1 Phosphorylation of T70 b0.001
FAK Expression 0.021
NF2 Expression 0.014
Rad51 Expression b0.001
PR Expression b0.001
Akt Phosphorylation of S473 0.012
Bcl.xL Expression 0.018
MIG.6 Expression 0.002
Cyclin_E1 Expression b0.001
S6 Expression b0.001
Phosphorylation and expression levels of 171 proteins measured with reverse phase protein arrays (RPP
and molecular subtype. Student t-test and Mann–Whitney test analyses defined protein alterations th
evaluated protein levels in relation to PIK3CA status combined with molecular subtype and used the
mutation status after linear regression. Of these, 9 proteins were of interest because their levels were
P-value based on Mann–Whitney U test;
† Residuals failed test for heteroskedasticity.
‡ Residuals failed test for normality.applied by us [10,11]. Briefly, tissue sampleswere used frompatients with
primary operable breast cancer between 1985 and 2000. This TMA
contained a cohort of 817 patients. Tumors were included for analyses if
histologic subtype, Bloom-Richardson score for tumor differentiation
grade, estrogen and progesterone receptor status (ER, PgR), HER2/neu,
epidermal growth factor receptor (EGFR) and cytokeratin 5 (CK5) status
were available. Above selection criteria resulted finally in the evaluation of
triplicate tissue core biopsies from 721 patients with primary breast
cancer. These included 526 luminal breast tumors amongst other
subtypes, of which 290 were from lymph node negative patients who
received no (neo)adjuvant systemic therapies as described previously (van
derWillik et al., AJCR 2016). This retrospective study with coded tumor
tissues was approved by the Erasmus MC medical ethics committee at
Rotterdam, The Netherlands (MEC 02.953). TMAs were stained with
the primary rabbit polyclonal antibody forMAPK1/3 phosphorylation at
1:200 dilution (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
Antibody #9101 from Cell Signaling Technology). The antibody was
incubated overnight at 4 °C after 20 minutes antigen retrieval at pH 6.0.
Subsequently, the TMA-slides were incubated with a secondary antibody
(Rabbit Envision + System, HRP (DAKO)) and staining was visualized
using diaminobenzidine (DAB).
Both nuclei and cytoplasm were scored for MAPK1/3 phosphor-
ylation by two independent observers with regard to staining intensity
and to the estimated proportion of tumor cells with positive nuclei
and/or cytoplasm within a core biopsy. These scores were categorized
to explore staining pattern differences. Negative versus positive
staining was evaluated for both nuclei and cytoplasm separately, and
combined since a subset of specimens showed heterogeneity in tumor
cell staining (see Figure 4). Positive staining was specified for its
intensity (weak, moderate, strong) and/or proportion of staining. To
have enough cases for proper evaluation, groups were taken together
to obtain more robust categories. For that reason, negative and weak
staining were combined into one category (weak), and moderate
and strong staining into another category (strong). In a similarlar Subtype
or Combined with Molecular Subtypes in 361 Tumor Specimens
U Test Multiple Linear Regression (Basal PIK3CA Wild-Types as Reference)
PIK3CA HER2 Luminal A Luminal B
b0.001 ‡ 0.883 0.054 0.933
0.001 0.155 0.002 0.679
0.009†,‡ 0.014 0.137 b0.001
0.001 0.053 0.58 0.001
0.001 0.003 0.12 b0.001
0.049 ‡ 0.734 b0.001 0.591
0.048 0.018 0.394 0.007
0.025 0.391 0.684 0.751
0.016†,‡ 0.195 b0.001 0.268
b0.001 † 0.974 b0.001 b0.001
0.002 0.138 0.013 b0.001
0.002†,‡ 0.836 0.011 0.003
0.017 ‡ 0.002 0.043 b0.001
0.008 ‡ b0.001 b0.001 b0.001
0.039 0.004 b0.001 b0.001
A) obtained from the TCGA database, were evaluated for their relationship with PIK3CA genotype
at are significantly related to PIK3CA status in all 361 tumor specimens. Multiple linear regression
wild-type basal-like subtype as reference. Only 15 protein alterations were significant for PIK3CA
altered due to PIK3CA (P b .05) but not by luminal subtype (P N .05).
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20% positivity (low) versus more than 20% positive nuclei or
cytoplasm (high).
PIK3CA Mutation Analysis
PIK3CA status were established by SnaPshot® multiplex assays (Life
technologies) as described previously [5]. For only 105, of which 95
luminals, out of the 721 cases, (sufficient) DNA was available from the
TMA core biopsies to identify PIK3CA exon 9 and exon 20 mutations.Results
Protein Expression and Phosphorylation Related to PIK3CA
Genotype and Molecular Subtypes
Student t-test or Mann–Whitney test analyses of proteins in 361
tumors, showed that 60 proteins had significant differences in expression or
phosphorylation levels between tumors mutant (N = 94) or wild-typeFigure 3. Protein alterations in PIK3CA exon-specific mutated lumin
proteins due to PIK3CA mutation status but not molecular subtype a
presents fold changes (FC) and P-values of non-parametrical Mann–
expression of p70S6K and 4E–BP1 in luminal A and B breast cancer(N = 267) forPIK3CA (Supplemental Table S1). Of these 60 proteins, 15
protein changes were significant (P b .05) in multiple linear regression
analyses for PIK3CA status when molecular subtypes were taken into
account (Figure 2, Table 1).
To identify protein alterations correlated with mutation and not with
subtype, only proteins were studied further for which expression level or
phosphorylation status was affected by thePIK3CAmutation status and not
significantly by subtype. Of the 15 proteins, the residuals of 11 proteins
showed that the assumptions for constant variance (4 failed tests for
heteroscedasticity) were valid allowing extrapolation of findings (Table 1).
Subsequently, 9 proteins had P valuesb.05 forPIK3CAmutation status and
P N .05 for luminal A and/or B subtypes (Table 1). Of these, MAPK1/3
phosphorylation andNF2 expression had significant different levels between
PIK3CA wild-types and mutants irrespective of molecular subtype.
The other proteins were differentially expressed or phosphorylated
due to PIK3CA status and subtype when compared to the wild-type
basal subtype. Only significant for PIK3CA mutation status andal breast cancer. Differential phosphorylation and expression of 5
s established in the multi-regression analysis (Table 1). The figure
Whitney U tests for MAPK1/3, p38 and YAP phosphorylation and
with exon 9 or exon 20 PIK3CA mutations.
Figure 4. Phosphorylated MAPK1/3 staining patterns examples defined by intensity and proportion of MAPK1/3 phosphorylated tumor
cells. Figure 4A. Negative for both nuclear and cytoplasmic. Figure 4B. Negative for nuclear and 100% moderate cytoplasmic intensity.
Figure 4C. 70% weak nuclear and 80% moderate cytoplasmic intensity. Figure 4D. 100% strong for both nuclear and cytoplasmic
intensity. Figure 4E. 100% strong nuclear and 100% moderate cytoplasmic intensity.
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expression and 4E–BP1 expression and phosphorylation, and in
luminal A the p38 and YAP phosphorylation and expression of
p70S6K and FAK. The applied (non)parametric tests have
demonstrated significant proteins alterations in the TCGA dataset.
For the findings on p70S6K, however, these may not be extrapolated
due to test limitations and/or assumptions.
PIK3CA Genotype Related Protein Alterations in Luminal
Breast Cancer
The altered expression and phosphorylation levels of the 9 selected
proteinswere further investigated in the luminal subsets, i.e. 147 luminal A
and 89 luminal B tumors (Supplemental Table S2). Two proteins, i.e.
NF2 and RAD51, showed no significant fold changes in this luminalFigure 5.MAPK1/3 phosphorylation immunohistochemical stainin
biopsies from 721 breast cancer patients were evaluated for nucle
present the percentage (above each bar) and number of cases (b
(Figure 5, C and D) defined by intensity (Figure 5, A and C) and b
of cases comparing MAPK1/3 phosphorylation between cytopla
(Figure 5F).g e
ar,
otto
y pr
smisubset when evaluated for all mutants together, and were excluded from
further analyses. In PIK3CA mutated specimens compared to wild-type
specimens significant fold changes were observed for the remaining 7
proteins with increasedMAPK1/3 phosphorylation seen in luminal A and
B cancers, decreased 4E–BP1 expression and phosphorylation in luminal
B tumors, and decreased p70S6K and FAK expression and increased p38
and YAP phosphorylation in luminal A typed specimens.
Protein Expression and Phosphorylation Related to PIK3CA
Exon 9 and 20 Mutations
Five of the 7 proteins altered in the luminal subset, all but FAK
expression and phosphorylation of 4E–BP1, were significantly related
to exon specific mutations when compared to wild-type counterparts
(Figure 3, Supplemental Table S2).valuation. Tissue microarrays containing primary breast tumor core
cytoplasmic and tumor cell MAPK1/3 phosphorylation. The figures
m values) for nuclear (Figure 5, A and B) and cytoplasmic staining
oportion (Figure 5, B and D). Additionally, it illustrates the number
c and nuclear staining for proportion (Figure 5E) and for intensity
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MAPK1/3 and YAP phosphorylation and decreased p70S6K
expression in luminal A, and only increased MAPK1/3 phosphory-
lation in luminal B (Figure 3). Tumors harboring exon 20 mutations
had increased MAPK1/3 and p38 phosphorylation in luminal A and
decreased expression of p70S6K in luminal A while only 4E–BP1 was
decreased in luminal B. The differences in phosphorylation observed
in our in silico analyses for p38 and YAP in relation to exon-specific
PIK3CA mutations, have not been yet reported by others to our
knowledge.Figure 6. MAPK1/3 phosphorylation in relation with intrinsic subtype
percentage (above each bar) and number of cases (bottom values) fo
cellular staining (Figure 6, E and F) defined by proportion (Figure 6,
subtypes were defined by ER, PgR, HER2/neu, EGFR and Cytokerat
27186402) as luminal (positive for ER and/or PgR, negative for HER2/n
or Cytokeratin 5, negative for ER, and HER2/neu). P-values are basedTumor Cell Heterogeneity and Subcellular Localization of
MAPK1/3 Phosphorylation
Protein functioning is not only defined by their expression and
phosphorylation status, but may also depend on (sub)cellular
localization. The RPPA findings, as described above, however, do
not reveal which cell types and cellular compartments express
proteins. To address this disadvantage, we examined MAPK1/3
phosphorylation for tumor cell heterogeneity and its subcellular
localization in TMAs containing core biopsies of 721 primary tumor
tissue specimens (Figures 4 & 5). Immunohistochemical staining fors analyzed in 721 primary breast tumors. The figures present the
r nuclear (Figure 6, A and B), cytoplasmic (Figure 6, C and D) and
A, C, and E) and by intensity (Figure 6, B, D, and F). The intrinsic
in 5 staining and classified as described previously by us (PMID:
eu), Her2 (positive for HER2/neu) and basal (positive for EGFR and/
on chi-square test.
862 Increased MAPK1/3 activity in PIK3CA mutated... Ramirez-Ardila et al. Translational Oncology Vol. 10, No. 5, 2017MAPK1/3 phosphorylation was performed, since it was the most
significant protein alteration seen in PIK3CA exon 9 mutant luminal
A and B tumors and in exon 20 mutant luminal A tumors (Figure 3).
Our TMA biopsies showed heterogeneity in staining patterns for
MAPK1/3 phosphorylation as illustrated by the examples of Figure 4
and quantified in Figure 5. Moreover, MAPK1/3 phosphorylation
was especially seen in the luminal and HER2 intrinsic subtypes,
whereas tumors of the basal subtype had somewhat less staining of
especially nuclei (Figure 6).
TheMAPK1/3 phosphorylation staining revealed besides tumors with
no and N80% positive tumor cells, also tumors with 11% to 80% tumor
cells with MAPK1/3 phosphorylation in their cytoplasm (18% inFigure 7.MAPK1/3 phosphorylation in relation toPIK3CAmutation status
percentage (above each bar) and number of cases (bottom values) for n
staining (Figure 7, E and F) defined by proportion (Figure 7, A, C, and E)
subcellular localization of MAKP1/3 phosphorylation with PIK3CAmutatiFigure 5D) and in their nuclei (32% in Figure 5B). These findings suggest
heterogeneity in a subset of specimens containing both tumor cell
populations positive as well as negative for MAPK1/3 phosphorylation.
Additionally, Figure 4 indicates heterogeneity in subcellular phosphor-
ylation ofMAPK1/3, which is confirmed by the staining distributions for
proportions and intensities between nuclei and cytoplasm, respectively, as
illustrated in Figure 5, E and F. For example, cases with no cytoplasmic
MAPK1/3 had weak to strong nuclear MAPK1/3 staining (Figure 5F) in
up to 100% of the nuclei (Figure 5E). Overall, the staining proportion
and intensity for MAPK1/3 phosphorylation was significantly heteroge-
neous (both chi-square test P b .001) when compared between nuclei
and cytoplasm.analyzed in 95 available luminal breast tumors. The figures present the
uclear (Figure 7, A and B), cytoplasmic (Figure 7, C and D) and cellular
and by intensity (Figure 7, B, D, and F). No association was found for
on status. P-values are based on chi-square test.
Table 2. Staining Intensity and Proportion for MAPK1/3 Phosphorylation in Nuclei and Cytoplasm of Tumor Cells and its Relationship with Metastasis-Free Survival: P-Value Log-rank Test for Trends
Staining Intensity and Proportion for MAPK1/3 Phosphorylation in Nuclei and Cytoplasm of Tumor Cells and its Relationship with Metastasis Free Survival in Breast Cancer: P-Values for Log-Rank Test
for Trends
Primary Breast Cancer (N = 721) Luminal Breast Cancer (N = 526) LNN Luminals (N = 290)
Staining Categories Number of Cases per Category P-Value Number of Cases per Category P-Value Number of Cases per Category P-Value
Nuclei
Intensity:
Negative versus Positive 72; 649 0.0225 34; 492 0.0163 18; 272 0.0376
Weak versus Strong 379; 342 0.0532 241; 285 0.0032 131; 159 0.0463
Proportion: Low (≤20%) versus High (N 20%) 94; 627 0.0928 48; 478 0.0167 23; 267 0.0049
Cytoplasm
Intensity:
Negative versus Positive 133; 588 0.0957 87; 439 0.0198 42; 248 0.1008
Weak versus Strong 533; 188 0.0912 379; 147 0.0728 205; 85 0.2085
Proportion: Low (≤20%) versus High (N 20%) 138; 583 0.1545 89; 437 0.0178 43; 247 0.0556
Tumor Cells (Nuclei and Cytoplasm Combined)
Intensity:
Negative versus Positive 57; 664 0.0106 28; 498 0.0003 14; 276 0.0058
Weak versus Strong 332; 389 0.0396 211; 315 0.0013 110; 180 0.0283
Proportion: Both Low versus Low/High versus Both High 62; 108; 551 0.0694 31; 75; 420 0.0039 15; 36; 239 0.0058
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MAPK1/3 phosphorylation was also evaluated in a subset 95
luminal breast cancers with known PIK3CA genotype, including 32
tumors with PIK3CA exon 9 (n = 9) or exon 20 mutations (n = 23).
No significant differences between PIK3CA mutants and wild-types
were observed for staining proportion and intensity of nuclei and
cytoplasm, when analyzed separately or combined (Figure 7).
Clinical Relevance of Subcellular Localization of MAPK1/3
Phosphorylation in Breast Cancer Tissue Specimens
Log-rank tests for trend were evaluated to determine whether
MAPK1/3 phosphorylation staining intensity and proportion were
related with MFS (Table 2). These tests demonstrated a relationship
with MFS in especially luminal tumors for nuclear and tumor cell
MAPK1/3 phosphorylation for both staining intensity and propor-
tion. In contrast, cytoplasmic staining was associated with MFS in
only 2 of 9 analyses.
MAPK1/3 phosphorylation staining patterns were evaluated for
their prognostic value in a cohort of luminal primary breast tumors
from 290 LNN patients who did not receive (neo)adjuvant systemic
therapy. Kaplan–Meier survival curve analyses and the log-rank
tests for trend showed that only nuclear and tumor cell staining
were related with MFS in this cohort (Table 2 and Figure 8). The
Kaplan–Meier analyses demonstrated that high (N20% in Figure 8A)
as well as strong (Figure 8D) nuclear MAPK1/3 phosphorylation
associate with favorable survival. Similar results were obtained for
tumor cell staining (Figure 8, C and F) but not for cytoplasmic
staining (Figure 8, B and E).
Uni- and multivariate analyses for MAPK1/3 phosphorylation
staining patterns were performed for this cohort of 290 LNN patients
(Table 3). Staining patterns in multivariate analyses were compared to
the base model of traditional prognostic factors which included age,
menopausal status, tumor size, Bloom-Richardson differentiation
grade and progesterone receptor status. Only high nuclear and tumor
cell stain staining proportions were independent from the traditional
factors and associated with favorable survival. MAPK1/3 phosphor-
ylation in more than 20% of nuclei was associated with longer MFS
compared to no or less than 20% of positive nuclei (HR = 0.49; 95%
CI: 0.25–0.95;P = .036). Similarly, in specimens with staining inmore than 20% of both nuclei and cytoplasm, MAPK1/3
phosphorylation was also related with favorable MFS (HR = 0.37;
95% CI: 0.18–0.79; P = .010).Discussion
This study aimed to reveal proteins downstream PI3K with altered
phosphorylation or expression levels in luminal breast cancer with
PIK3CA exon 9 and/or exon 20 mutations. Our in silico analyses
of publically available RPPA data showed in luminal A and B tumors
with PIK3CA mutations an increased phosphorylation of MAPK1/3,
p38 and YAP and decreased expression of p70S6K and 4E–BP1. We
showed that MAPK1/3 phosphorylation was the most significant
protein up-regulated in PIK3CA exon 9 mutated luminal A and B
tumors and in PIK3CA exon 20 mutated luminal A tumors. Our
immunohistochemical staining of MAPK1/3 phosphorylation on
TMAs demonstrated tumor cell heterogeneity in subcellular location,
staining intensity and proportion. We demonstrated that high MAPK
phosphorylation in especially the nuclei of tumor cells correlated with
favorable prognosis.
We investigated protein changes detected by RPPA to identify
alterations specific for luminal breast cancer specimens with a
PIK3CA exon 9 or exon 20 mutation. Mutations in PIK3CA, next to
TP53, occur most frequently in breast cancer. TP53 mutations and
PI3K/AKT/mTOR pathway activation are particularly observed in
breast cancer of the basal subtype [1]. The PIK3CA mutations,
however, are predominantly observed in ER-positive tumors and have
been shown to be present in approximately 27% of luminal B up to
45% in luminal A specimens [1]. Above considerations were taken
into account in our in silico analyses using a multi-regression model
combining PIK3CA status and molecular subtype. These analyses
helped to identify alterations related to the PIK3CA mutation status
in a (luminal) subtype independent way. Although 15 protein
changes had a significant relation with PIK3CA mutation status, only
9 of these were not correlated with luminal A and/or B subtypes.
These 9 proteins were further explored within the subset of 236
luminal specimens for the relation with exon-specific PIK3CA
mutations. This subsequent in silico evaluation demonstrated just 5
of these 9 protein alterations to be PIK3CA exon mutation specific in
Figure 8. Subcellular localization of phosphorylated MAPK1/3 and its prognostic significance. Kaplan Meier curve analyses for MFS in
luminal primary breast tumors of 290 (neo) adjuvant systemic therapy naïve LLN patients shows that high (Figure 8A) and strong
(Figure 8D) nuclear MAPK1/3 phosphorylation correlates with favorable prognosis. No correlation was observed for cytoplasmic
phosphorylated MAPK1/3 regarding staining proportion (Figure 8B) and intensity (Figure 8E). Finally, nuclear and cytoplasmic staining
combined (cellular staining) was associated with favorable prognosis when defined by proportion (Figure 8C) as well as by intensity
(Figure 8F). Abbreviations: MFS: Metastasis-free survival; LNN: Lymph Node Negative.
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MAPK1/3, p38 and YAP and decreased expression of p70S6K and
4E–BP1. Future investigations are needed to validate our in silico
results in other subsets.
Differences in protein phosphorylation patterns in relation to
PIK3CA mutations have been reported for human cancer cell line
models. It was shown that somatic knock-in of both KRAS andPIK3CA mutations in human breast epithelial cells was accompanied
by increased MAPK1/3 phosphorylation, MAPK pathway activation,
and tumor formation in immune-comprised mice [12]. Moreover, it
was shown that phosphorylation of MAPK1/3 resulted in an
activation of the protein and translocation from the cytoplasm to
the nucleus [13]. We could not evaluate this translocation of
MAPK1/3 upon phosphorylation with the available RPPA data from
Table 3. Univariate and Multivariate Analyses for Metastasis-Free Survival of MAPK Phosphorylation
Uni- and Multivariate Analyses of MAPK1/3 Phosphorylation: Its Relationship with Metastasis-Free Survival in 290 Luminal Lymph Node Negative (Neo)Adjuvant Systemic Therapy Naïve Breast
Cancer Patients
Univariate Analysis Multivariate Analysis
Factor Number Patients % HR 95% CI P-Value HR 95% CI P-Value
Age at diagnosis (in years):
b40 26 9% 1.00 1.00
41–55 116 40% 0.75 0.37–1.53 0.432 0.73 0.34–1.55 0.412
56–70 101 35% 0.56 0.26–1.20 0.135 0.26 0.09–0.79 0.018
N70 47 16% 0.81 0.34–1.92 0.634 0.31 0.09–1.03 0.057
Menopausal status:
premenopausal 126 43% 1.00 1.00
postmenopausal 164 57% 0.99 0.63–1.57 0.995 2.32 1.03–5.20 0.042
tumor size (cm):
b2 cm 196 68% 1.00 1.00
≥2 cm 94 32% 2.37 1.51–3.73 b0.001 2.34 1.47–3.74 b0.001
Differentiation grade:
1 68 23% 1.00 1.00
2 153 53% 2.12 1.07–4.23 0.032 1.79 0.89–3.60 0.104
3 69 24% 3.05 1.46–6.37 0.003 2.67 1.26–5.68 0.011
PgR status:
negative 63 22% 1.00 1.00
positive 227 78% 0.82 0.48–1.40 0.462 0.82 0.46–1.43 0.477
Staining of MAPK1/3 Phosporylation added to base model
Nuclei
Intensity
Negative 18 6% 1.00 1.00
Positive 272 94% 0.49 0.24–0.97 0.042 0.58 0.27–1.25 0.165
Weak 131 45% 1.00 1.00
Strong 159 55% 0.63 0.40–0.99 0.048 0.77 0.47–1.25 0.293
Proportion:
Low (≤20%) 23 8% 1.00 1.00
High (N 20%) 267 92% 0.42 0.23–0.79 0.006 0.49 0.25–0.95 0.036
Cytoplasm
Intensity
Negative 42 14% 1.00 1.00
Positive 248 86% 0.63 0.36–1.10 0.104 0.69 0.39–1.22 0.203
Weak 205 71% 1.00 1.00
Strong 85 29% 0.71 0.42–1.21 0.211 0.78 0.46–1.34 0.377
Proportion:
Low (≤20%) 43 15% 1.00 1.00
High (N 20%) 247 85% 0.59 0.34–1.02 0.059 0.64 0.36–1.13 0.121
Tumor cells (nuclei and cytoplasm combined)
Intensity:
Negative 14 5% 1.00 1.00
Positive 276 95% 0.37 0.18–0.77 0.008 0.42 0.19–0.92 0.029
Weak 110 38% 1.00 1.00
Strong 180 62% 0.61 0.39–0.95 0.030 0.78 0.49–1.27 0.319
Proportion:
both low 15 5% 1.00 1.00
low/high 36 12% 0.40 0.16–0.99 0.047 0.39 0.15–1.02 0.056
both high 239 82% 0.33 0.16–0.67 0.002 0.37 0.18–0.79 0.010
Analyses performed in 290 patients with luminal LNN breast tumors. The 290 patients did not receive adjuvant systemic therapy. Abbreviations: LNN: Lymph Node Negative; HR: Hazard ratio; PgR:
Progesterone receptor.
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lysates of cancer tissue and not on protein lysates of nuclear and
cytoplasmic fractions. Therefore, we performed an immunohisto-
chemical staining for MAPK1/3 phosphorylation on TMAs contain-
ing core biopsies of breast cancer specimens. These stainings enabled
us to establish the subcellular location of MAPK1/3 phosphorylation
and to examine tumor cell heterogeneity. Our results detected in 32%
of cases nuclear MAPK1/3 phosphorylation for only a subset of tumor
cells (ranging from 20% to 80%). This suggests that MAPK
activation is not always seen in all tumor cells for a substantial subset
of breast cancers.
Importantly, high MAPK1/3 phosphorylation in nuclei was related
with favorable prognosis in our cohort of LNN luminal breast cancerspecimens. Others have stained tissue microarrays for MAPK1/3
phosphorylation in breast cancer to determine either the relation with
PI3K or with clinical outcome. Nuclear MAPK1/3 phosphorylation
was investigated on 563 estrogen receptor positive primary tumors
from patients participating in a randomized trial of 1 to 3 years
adjuvant tamoxifen [14,15]. One study showed that at baseline both
PIK3CA exon 9 and 20 mutated specimens have higher MAPK1/3
phosphorylation levels compared to wild-types [14]. Although this
association with PIK3CA mutations was not confirmed in our TMA
cohort, this is explained by the small number of cases for which the
PIK3CA status could be determined. The other study demonstrated
a trend between tamoxifen response and MAPK1/3 phosphorylation
[15]. Additionally, nuclear and cytoplasmic MAPK1/3
866 Increased MAPK1/3 activity in PIK3CA mutated... Ramirez-Ardila et al. Translational Oncology Vol. 10, No. 5, 2017phosphorylation were also studied in large well-characterized breast
cancer series to investigate its biological and clinical significance
[16,17]. This study showed that nuclear MAPK1/3 phosphorylation
was associated with better outcome, especially in tamoxifen-treated
cases. All these immunohistochemical studies in large cohorts of
(luminal) breast cancer specimens confirm in part our in silico
findings in relation to PIK3CA mutation [18] and our TMA findings
that nuclear MAPK1/3 phosphorylation correlates with favorable
outcome [16,17]. Future prospective studies are needed to verify
above retrospective findings and to establish MAPK1/3 phosphory-
lation as biomarker.
In conclusion, we have explored several methods combining in
silico multivariate analyses and immunocytochemistry on luminal
breast cancer specimens. We have shown that PIK3CA mutated
breast tumor specimens are characterized in an exon dependent
manner by increased MAPK1/3 phosphorylation. The observed
relationships in clinical specimens indicate that the phosphorylation
of MAPK1/3 and its subcellular localization might associate with
clinical outcome. Considering the high prevalence of PIK3CA
mutations in breast cancer, our findings will aid in the design of
future studies to evaluate and/or target downstream effectors of the
PIK3CA mutation. Our findings indicate that MAPK1/3 phosphor-
ylation may play an important role as a target downstream effector in
luminal breast cancer patients with a PIK3CA mutation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2017.08.002.
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